Evidence map›Paper›PMID 19850645›Full record

ArticleJournal of molecular endocrinology2010

Rosiglitazone activation of PPARgamma suppresses fractalkine signaling.

Yihong Wan, Ronald M Evans

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of molecular endocrinology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Molecular determinants of lung development.Annals of the American Thoracic Society · 2013
    Review
  12. Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Yihong WanDepartment of Pharmacology, University of Texas Southwestern Medical Center, 6001 Forest Park Road, Room ND8.502B, Dallas, Texas 75390-9041, USA. yihong.wan@utsouthwestern.edu
Ronald M Evans
Salk Institute for Biological Studies · USThe University of Texas Southwestern Medical Center · US

Funding

HORMONAL REGULATION OF MAMMALIAN GENE EXPRESSIONR37DK057978 · NIDDK · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI EVANS, RONALD M · 2000 to 2019
$16.0M
SCOR IN MOLECULAR MEDICINE AND ATHEROSCLEROSISP50HL056989 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WITZTUM, JOSEPH L. · 1997 to 2006
$14.1M
SPATIAL REGULATION OF DEVELOPMENTAL GENE EXPRESSIONR01HD027183 · NICHD · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI EVANS, RONALD M · 1990 to 2009
$3.6M
Hormonal Regulation of Mammalian Gene ExpressionR01DK057978 · NIDDK · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI EVANS, RONALD M · 2021 to 2024
$2.6M
Howard Hughes Medical InstituteNHLBI NIH HHS HL56989NHLBI NIH HHS P50 HL056989NICHD NIH HHS HD027183NICHD NIH HHS R01 HD027183NIDDK NIH HHS DK057978NIDDK NIH HHS R01 DK057978NIDDK NIH HHS R37 DK057978
6 · The paper itself

Abstract

The nuclear receptor peroxisome proliferator-activated receptor gamma (PPARgamma) is a key transcriptional regulator of both lipid metabolism and inflammation. The importance of PPARgamma is accentuated by the widespread use of synthetic PPARgamma agonists, thiazolidinediones (such as rosiglitazone), as drugs for insulin resistance and type II diabetes. Fractalkine (FKN) and FKN receptor (FR) play an important role in the immune responses by regulating leukocyte migration and adhesion to inflamed peripheral tissues. In this study, we have identified a novel link between PPARgamma activation and FKN signaling. On one hand, the activation of PPARgamma by rosiglitazone in macrophages not only represses the transcription of the FR gene, but also prevents the plasma membrane translocation of the FR protein. On the other hand, the activation of PPARgamma by rosiglitazone in endothelial cells also impedes the nuclear export of FKN. Together, these data suggest that PPARgamma activation represses FKN signaling. These findings indicate a previously unrecognized mechanism that may contribute to the anti-inflammatory effect of PPARgamma.

Indexed as

Active Transport, Cell NucleusAnimalsCell LineCell MembraneCell NucleusChemokine CX3CL1Down-RegulationEndothelial CellsHumansMacrophagesMicePPAR gammaPromoter Regions, GeneticProtein TransportRosiglitazoneSignal TransductionChemokine CX3CL1PPAR gammaRosiglitazoneThiazolidinediones

Identifiers

PMID19850645
PMCPMC2805405
OpenAlexW2090862753

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.